Products & Pipeline

Laromustine (Cloretazine®, VNP40101M) is being evaluated for the treatment of acute myelogenous leukemia (AML) in a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition, three clinical trials of laromustine (Cloretazine®, VNP40101M) are underway in: (i) elderly AML and myelodysplastic syndromes in combination with cytarabine; (ii) brain tumors in combination with temozolomide; and (iii) advanced hematologic malignancies in combination with hematopoietic cell transplantation.

Triapine® is designed to prevent the replication of tumor cells by blocking ribonucleotide reductase, an enzyme critical to DNA synthesis and repair. Triapine® is in clinical trials sponsored by the National Cancer Institute.

VNP40541 is a noval cytotoxic agent in late stage preclinical development. It is a prodrug which, in preclinical studies, is preferentially activated in hypoxic conditions.

Hydrazones are anticancer compounds that have demonstrated potent antitumor effects in preclinical studies.

TAPET® is a modified Salmonella vector used to deliver anticancer agents directly to tumors .